Medicenna Therapeutics Corp.
NASDAQ:MDNA
0.157 (USD) • At close September 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 9.304 | 14.716 | 10.87 | 5.87 | 3.018 | 5.09 | 4.229 | 0.771 | 0.001 | 0.001 |
General & Administrative Expenses
| 6.994 | 7.72 | 6.485 | 2.493 | 2.209 | 2.997 | 4.016 | 0.47 | 0 | 0 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 6.994 | 7.72 | 6.485 | 2.493 | 2.209 | 2.997 | 4.016 | 0.47 | 0 | 0 |
Other Expenses
| 0.005 | 0.037 | 0.04 | -0.117 | -0.499 | 0 | 0 | 0 | 0 | 0 |
Operating Expenses
| 16.303 | 22.473 | 17.395 | 8.245 | 4.727 | 7.425 | 7.698 | 1.2 | 0.001 | 0.001 |
Operating Income
| -21.643 | -22.3 | -17.187 | -8.206 | -4.727 | -7.381 | -7.665 | -1.2 | -0.001 | -0.001 |
Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 11.595 | -0.277 | -0.102 | -0.071 | 0.019 | -0.044 | 0.034 | -0.134 | -0 | -0 |
Income Before Tax
| -10.048 | -22.577 | -17.289 | -8.277 | -4.708 | -7.465 | -7.631 | -1.334 | -0.001 | -0.001 |
Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| -11.595 | 0.069 | -0.106 | 0.032 | 0.019 | 0.041 | 0 | 0 | 0 | -0 |
Net Income
| 1.547 | -22.646 | -17.183 | -8.309 | -4.708 | -7.465 | -7.631 | -1.334 | -0.001 | -0.001 |
Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| 0.024 | -0.42 | -0.35 | -0.26 | -0.18 | -0.31 | -0.45 | -0.083 | -0.053 | -0.049 |
EPS Diluted
| 0.024 | -0.42 | -0.35 | -0.26 | -0.18 | -0.31 | -0.45 | -0.083 | -0.053 | -0.049 |
EBITDA
| -21.639 | -22.262 | -17.147 | -8.198 | -4.74 | -7.371 | -7.659 | -1.198 | -0.001 | -0 |
EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |